Biologic agents and rheumatoid arthritis Archives

Abstract Number: 551 • ACR/ARHP Annual Meeting 2017
Comparison of Drug Tolerability and Discontinuation Reasons between 7 Biologics in Patients with Rheumatoid Arthritis -Results from Kansai Consortium for Well-Being of Rheumatic Disease Patients (ANSWER cohort)-
Kosuke Ebina¹, Makoto Hirao², Motomu Hashimoto³, Moritoshi Furu⁴, Wataru Yamamoto⁵, Ryota Hara⁶, Takanori Fujimura⁶, Toru Hirano⁷, Shuzo Yoshida⁸, Koji Nagai⁸, Hideki Amuro⁹, Yonsu Son⁹, Akira Onishi¹⁰, Kengo Akashi¹¹, Masaki Katayama¹², Keiichi Yamamoto¹³ and Hideki Yoshikawa¹⁴, ¹Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, ²Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ³Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Kurashiki Sweet Hospital, Okayama, Japan, ⁶The Center for Rheumatic Diseases, Nara Medical University, Kashihara, Japan, ⁷Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan, ⁸Osaka Medical College, Osaka, Japan, ⁹Kansai Medical University, Osaka, Japan, ¹⁰Kobe University Graduate School of Medicine, Kobe, Japan, ¹¹Department of Rheumatology and Clinical Immnology, Kobe University Graduate School of Medicine, Kobe, Japan, ¹²Osaka Red Cross Hospital, Osaka, Japan, ¹³Osaka City University, Osaka, Japan, ¹⁴Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: 　More than 4 years have passed since 7 biologics became available for patients with rheumatoid arthritis (RA) in Japan, still lack reliable evidence in…
Abstract Number: 1660 • ACR/ARHP Annual Meeting 2015
Two-Year Prospective Study of Patients with Rheumatic Disease on Dose Reduction of Biological Therapy
M. Victoria Hernández¹, Jose Inciarte-Mundo², Sonia Cabrera-Villalba³, Virginia Ruiz-Esquide⁴, Julio Ramirez², Andrea Cuervo⁴, Juan D. Cañete^4,5 and Raimon Sanmarti², ¹Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain, ²Arthritis Unit. Rheumatology, Hospital Clínic of Barcelona, Barcelona, Spain, ³Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, ⁴Arthritis Unit. Rheumatology, Hospital Clínic, Barcelona, Spain, ⁵Hospital Clinic, Barcelona, Arthritis Unit, Rheumatology Department, Barcelona, Spain
Background/Purpose: Dose reduction of biological therapy in patients with chronic arthritis (CA) with good clinical response is a common pattern in clinical practice. However, most…
Abstract Number: 2340 • ACR/ARHP Annual Meeting 2013
Persistent Use Of Biologic Therapies At Lower Than Recommended Dosing Among Rheumatoid Arthritis Patients Enrolled In The US Medicare Program
Jie Zhang¹, Fenglong Xie², Elizabeth S. Delzell³, Huifeng Yun³, James Lewis⁴, Kevin Haynes⁵, Lang Chen⁶, Kenneth G. Saag⁷ and Jeffrey R. Curtis⁸, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Clinical Epidemiology and Biostatistics, University of Pennsylvania., Philadelphia, PA, ⁶Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁸University of Alabama at Birmingham, Birmingham, AL
Title: Persistent Use of Biologic Therapies at Lower Than Recommended Dosing among Rheumatoid Arthritis Patients Enrolled in the US Medicare ProgramBackground/Purpose: Biologic therapy is associated…

Abstracts tagged "Biologic agents and rheumatoid arthritis"

Comparison of Drug Tolerability and Discontinuation Reasons between 7 Biologics in Patients with Rheumatoid Arthritis -Results from Kansai Consortium for Well-Being of Rheumatic Disease Patients (ANSWER cohort)-

Two-Year Prospective Study of Patients with Rheumatic Disease on Dose Reduction of Biological Therapy

Persistent Use Of Biologic Therapies At Lower Than Recommended Dosing Among Rheumatoid Arthritis Patients Enrolled In The US Medicare Program